{"id":"W3004517814","doi":"10.1200/jco.2020.38.4_suppl.512","title":"Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Subgroup analyses from CheckMate 040.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Tolerability; Clinical endpoint; Nivolumab; Sorafenib; Oncology; Hepatocellular carcinoma; Clinical trial; Adverse effect; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002320806,0.001209869,0.002270768,0.0007361433,0.0002069325,0.0008523185,0.0005387761,0.0007360076,0.00315819],"category_scores_gemma":[0.002336847,0.000337673,0.0104837,0.0007064241,0.0002752001,0.0004548788,0.0006662059,0.001189557,0.0003325247],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007901147,"about_ca_system_score_gemma":0.0008652227,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001187519,"about_ca_topic_score_gemma":0.004970408,"domain_scores_codex":[0.9989533,0.0004611709,0.0001809909,0.0001658761,0.0001047609,0.0001337522],"domain_scores_gemma":[0.9991779,0.0003127925,0.0002152963,0.0001294219,0.00005250224,0.0001120638],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.7507349,0.001414501,0.05264252,0.00664184,0.1164549,0.0005349605,0.0002325283,0.002486986,0.008247836,0.0003082136,0.004724185,0.0555766],"study_design_scores_gemma":[0.3885643,0.07374767,0.2159543,0.00102369,0.288965,0.001363297,0.0005846508,0.007392756,0.004456275,0.002885469,0.01482505,0.0002375965],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9565226,0.03060731,0.001328782,0.0007525613,0.0004392806,0.002424411,0.005597902,0.00006583776,0.002261412],"genre_scores_gemma":[0.9897863,0.002678831,0.0008639751,0.0004973057,0.0002047445,0.001620352,0.003360012,0.00001768146,0.0009708251],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00315819,"threshold_uncertainty_score":0.01227379,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1262848890606197,"score_gpt":0.4145940628992987,"score_spread":0.288309173838679,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}